Protocol to study the antitumor and metabolic effects of intermittent fasting plus cisplatin and metformin in ovarian cancer PDX models
Different dietary regimens are being explored as safe, low-cost approaches to enhance cancer therapy. This protocol describes the evaluation of antitumor and metabolic effects of intermittent fasting (IF) combined with cisplatin and metformin in an ovarian cancer patient-derived xenograft (PDX) model. Procedures include IF cycles, drug administration, antitumor activity assessment, drug quantification in plasma and tumors, toxicity evaluation, and immunohistochemical analyses. For complete information on the generation and use of this protocol, please refer to Capellini et al. 1
Authors
- Federica Guffanti (ORCID: https://orcid.org/0000-0001-7723-9974)
- Cristina Matteo (ORCID: https://orcid.org/0000-0001-8910-1104)
- Francesca Ricci (ORCID: https://orcid.org/0000-0003-1705-186X)
- Daniela Corna (ORCID: https://orcid.org/0000-0002-7907-3047)
- Domenico Cerullo (ORCID: https://orcid.org/0000-0001-9806-6443)
- Eugenio Scanziani (ORCID: https://orcid.org/0000-0003-3996-5048)
- Elena Capellini (ORCID: https://orcid.org/0009-0006-0688-681X)
- Ludovica Perotti
- Federica Maggi
- Laura Sala
- Laura Brunelli
- Giovanna Damia
- Flavia Funari
- Anna Maria Ronchi
- Melissa Tiddia
Institutions
- University of Milan (IT)
- Mario Negri Institute for Pharmacological Research (IT)
- Istituti Clinici Scientifici Maugeri (IT)
- Fondazione Salvatore Maugeri (IT)
- Fondazione Filarete (IT)
Publication Details
- Journal
- STAR Protocols
- Published
- 2026-07-27
- DOI
- https://doi.org/10.1016/j.xpro.2026.104736
- Primary Topic
- Dietary Effects on Health
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Associazione Italiana per la Ricerca sul Cancro